MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review

A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.

Lire la suite...

MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal

The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.

Lire la suite...

Essais cliniques sur les cellules souches mésenchymateuses : ce que l’ISCT de Dublin a révélé sur la réparation du ménisque, le transfert mitochondrial et l’approvisionnement en cellules

A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.

Lire la suite...
Haut